Loading...
Market
Will Rybrevant become the top-selling EGFR-mutated NSCLC treatment in the US by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Sales data from J&J's financial reports and market analysis reports
Story
FDA Approves J&J's Rybrevant for EGFR-Mutated NSCLC, Third New Indication in 2024
Sep 19, 2024, 10:21 PM
The U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with standard care for the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). This approval marks the first targeted regimen to significantly reduce the risk of disease progression by more than half in the second-line setting and is the third new indication for Johnson & Johnson (J&J) in 2024. This development is part of a broader trend of advancements in lung cancer treatment, highlighted at the 2024 IASLC World Conference on Lung Cancer (WCLC24).
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Yes • 50%
No • 50%